The chromatin-remodeling enzyme BRG1 promotes colon cancer progression via positive regulation of WNT3A

Shengtao Lin; Tao Jiang; Ling Ye; Zhongbo Han; Yuan Liu; Chenchen Liu; Chenwei Yuan; Senlin Zhao; Jian Chen; Jingtao Wang; Huamei Tang; Su Lu; Liguang Yang; Xiaoliang Wang; Dongwang Yan; Zhihai Peng; Junwei Fan

doi:10.18632/oncotarget.13326

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

The chromatin-remodeling enzyme BRG1 promotes colon cancer progression via positive regulation of WNT3A

Shengtao Lin, Tao Jiang, Ling Ye, Zhongbo Han, Yuan Liu, Chenchen Liu, Chenwei Yuan, Senlin Zhao, Jian Chen, Jingtao Wang, Huamei Tang, Su Lu, Liguang Yang, Xiaoliang Wang, Dongwang Yan, Zhihai Peng and Junwei Fan _

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2016; 7:86051-86063. https://doi.org/10.18632/oncotarget.13326

Metrics: PDF 2770 views | HTML 2770 views | ?

Abstract

Shengtao Lin1,*, Tao Jiang2,*, Ling Ye1, Zhongbo Han3, Yuan Liu1, Chenchen Liu1, Chenwei Yuan1, Senlin Zhao1, Jian Chen1, Jingtao Wang1, Huamei Tang4, Su Lu4, Liguang Yang5, Xiaoliang Wang1, Dongwang Yan1, Zhihai Peng1, Junwei Fan1

1Department of General Surgery, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200080,China

2Department of Anal-Colorectal Surgery, General Hospital of Ningxia Medical University, Yinchuan 750004, China

3Department of General Surgery, Central Hospital of Zi Bo, Zi Bo, Shandong 255000, China

4Department of Pathology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200080, China

5Key Lab of Systems Biology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai 200031, China

*These authors contributed equally to this work

Correspondence to:

Junwei Fan, email: [email protected]

Zhihai Peng, email: [email protected]

Keywords: BRG1, colon cancer, progression, WNT3A

Received: June 15, 2016 Accepted: November 07, 2016 Published: November 12, 2016

ABSTRACT

In this study, we aimed to elucidate the clinical significance and underlying mechanisms of BRG1 in colon cancer. In the clinical analysis, overexpression of BRG1 correlates with colon cancer progression in two cohorts (n = 191 and n = 75). Kaplan-Meier survival analysis revealed that BRG1 is a prognosis predictor for overall survival (P < 0.001) and disease-free survival (P = 0.001). Knocking down BRG1 expression significantly suppressed the proliferation and invasion in colon cancer cells. The expression pattern of WNT3A is consistent with BRG1 in colon cancer tissues and WNT3A expression was inhibited in BRG1 knockdown cells. In addition, restoring WNT3A expression rescues the inhibition of cell proliferation and invasion induced by BRG1. In this study, we demonstrate that BRG1 may contribute to colon cancer progression through upregulating WNT3A expression.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 13326

Publication Alerts

Research Papers:

The chromatin-remodeling enzyme BRG1 promotes colon cancer progression via positive regulation of WNT3A

Abstract